Compile Data Set for Download or QSAR
Report error Found 708 Enz. Inhib. hit(s) with all data for entry = 6678
TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145281(US8952169, 60 | US9771376, Example 60)
Affinity DataIC50: 0.300nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145285(US8952169, 64 | US9771376, Example 64)
Affinity DataIC50: 0.400nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145281(US8952169, 60 | US9771376, Example 60)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145369(US8952169, 148 | US9771376, Example 148)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145371(US8952169, 150 | US9771376, Example 150)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145374(US8952169, 153)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145384(US8952169, 163)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145412(US8952169, 191)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM47139(US8952169, 175 | US8952169, 295)
Affinity DataIC50: 1nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM47141(US8952169, 185 | US8952169, 297)
Affinity DataIC50: 1nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145307(US8952169, 86 | US9771376, Example 86)
Affinity DataIC50: 1.31nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145369(US8952169, 148 | US9771376, Example 148)
Affinity DataIC50: 1.40nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145641(US8952169, 446)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145285(US8952169, 64 | US9771376, Example 64)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145379(US8952169, 158)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145392(US8952169, 267 | US8952169, 171)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145432(US8952169, 211)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145392(US8952169, 267 | US8952169, 171)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145623(US8952169, 426)
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM47137(US8952169, 270)
Affinity DataIC50: 2nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145470(US8952169, 249)
Affinity DataIC50: 2nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145485(US8952169, 269)
Affinity DataIC50: 2nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM47137(US8952169, 270)
Affinity DataIC50: 2nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145576(US8952169, 373)
Affinity DataIC50: 2nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145593(US8952169, 391)
Affinity DataIC50: 2nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145284(US8952169, 63 | US9771376, Example 63)
Affinity DataIC50: 2.10nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145270(US8952169, 49)
Affinity DataIC50: 2.20nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145270(US8952169, 49)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145307(US8952169, 86 | US9771376, Example 86)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145377(US8952169, 156)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145385(US8952169, 164)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145390(US8952169, 169 | US9771376, Example 169)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145442(US8952169, 221)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145456(US8952169, 235)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145481(US8952169, 262)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145531(US8952169, 327)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145591(US8952169, 389)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145592(US8952169, 390)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145609(US8952169, 412)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145624(US8952169, 427)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145516(US8952169, 430 | US8952169, 433 | US8952169, 312)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145632(US8952169, 435)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145284(US8952169, 63 | US9771376, Example 63)
Affinity DataIC50: 3nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145442(US8952169, 221)
Affinity DataIC50: 3nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145516(US8952169, 430 | US8952169, 433 | US8952169, 312)
Affinity DataIC50: 3nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145594(US8952169, 392)
Affinity DataIC50: 3nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145610(US8952169, 413)
Affinity DataIC50: 3nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145411(US8952169, 190)
Affinity DataIC50: 3.10nMpH: 7.4 T: 2°CAssay Description:Radioligand Binding Studies: Saturation experiments. A representative compound of formula (I) was tritiated. Three tritiums were incorporated in plac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145276(US8952169, 55)
Affinity DataIC50: 3.10nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM145641(US8952169, 446)
Affinity DataIC50: 3.10nMT: 2°CAssay Description:Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (NaV's), and all...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2015
Entry Details
Go to US Patent

Displayed 1 to 50 (of 708 total ) | Next | Last >>
Jump to: